The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Following a yearlong trial of Vertex's oral protease inhibitor, telaprevir's high success rate in clearing Hepatitis C from previous non-responders has landed it in the final stretch for FDA approval.
Continue reading »An interferon-free combination of four different drugs taken orally demonstrates encouraging initial results for reducing Hepatitis C viral load.
Continue reading »Data from a clinical trial brings hope for a DNA-based therapeutic vaccine for Hepatitis C.
Continue reading »Dosing has started for a Phase 2b study of Locteron®, an every-other-week, controlled release, interferon alpha-2b medication to treat Hepatitis C.
Continue reading »Already approved in Europe and the United States, Viraferonpeg combination therapy is now approved for re-treating Hepatitis C non-responders in India.
Continue reading »By investigating co-infection and interferon therapy, two Italian studies look into the future of Hepatitis B and Hepatitis C therapy.
Continue reading »Opening up new treatment possibilities, researchers from Scripps Institute have found molecules that prevent Hepatitis C viral production.
Continue reading »Because it showed potency against Hepatitis C in vitro, Abbott and Enanta Pharmaceuticals are beginning their first human trial for ABT-450. If this protease inhibitor fares well in healthy humans, it will progress to the next stage of testing.
Continue reading »Learn why Rockefeller University scientists' recent discovery on how to infect mice with Hepatitis C could lead to a necessary HCV vaccine.
Continue reading »By targeting p7, a protein that helps Hepatitis C spread, British researchers believe that combination therapies will be more effective at defeating the virus.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
